Hormone-resistant prostate carcinoma
MONDO:0056814Prostate carcinoma that does not respond to hormone therapy.
Also known as: hormone-resistant prostate cancer, hormone-resistant prostate carcinoma
2780 clinical trials for this condition and its sub-types, 30 tagged with Hormone-resistant prostate carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a vaccine plus immune booster tackle resistant prostate cancer?
Disease control Not yet recruitingThis early-phase trial is testing whether combining two immune-based treatments—Sipuleucel-T, a vaccine made from a patient's own immune cells, and N-803, a drug that boosts immune activity—is safe and tolerable for men with metastatic prostate cancer that has stopped responding …
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
A sharper eye on prostate cancer return: PSMA PET vs. MRI
Diagnosis Not yet recruitingThis pilot study investigates whether a PSMA PET scan, using an injected radiotracer, can detect clinically significant prostate cancer recurrence one year after focal HIFU treatment, compared with the standard MRI. About 30 men with prostate cancer who meet specific criteria wil…
Phase 4 • Sponsor: University Hospital, Toulouse • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
New scan could sharpen prostate cancer detection
Diagnosis Not yet recruitingThis study will compare a newer imaging method called 18F-PSMA PET/CT with the standard CT scan for prostate cancer patients. The goal is to see if the new scan is better at finding cancer initially, checking how well treatment is working, and detecting cancer that has come back.…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
Can a 2-week drug boost scan accuracy for hidden prostate cancer?
Knowledge-focused Not yet recruitingThis study looks at whether taking bicalutamide for two weeks can make PSMA PET/CT scans better at finding small amounts of prostate cancer that standard scans might miss. It involves 20 men with recurrent prostate cancer and very low PSA levels. Participants are randomly assigne…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC